AstraZeneca (AZN) – Research Analysts’ Recent Ratings Changes

A number of research firms have changed their ratings and price targets for AstraZeneca (LON: AZN):

  • 10/9/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at Barclays PLC. They now have a GBX 8,200 ($107.15) price target on the stock.
  • 10/8/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 10/8/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Bank of America Corp. They now have a GBX 8,500 ($111.07) price target on the stock.
  • 10/1/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 10/1/2019 – AstraZeneca had its “reduce” rating reaffirmed by analysts at HSBC Holdings plc. They now have a GBX 5,180 ($67.69) price target on the stock.
  • 9/30/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG.
  • 9/30/2019 – AstraZeneca was given a new GBX 6,550 ($85.59) price target on by analysts at Jefferies Financial Group Inc. They now have a “neutral” rating on the stock.
  • 9/30/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 9/30/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Deutsche Bank AG. They now have a GBX 7,800 ($101.92) price target on the stock.
  • 9/23/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/20/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 9/18/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 9/16/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co.. They now have a GBX 7,900 ($103.23) price target on the stock.
  • 9/13/2019 – AstraZeneca had its price target raised by analysts at Barclays PLC from GBX 8,000 ($104.53) to GBX 8,200 ($107.15). They now have an “overweight” rating on the stock.
  • 9/13/2019 – AstraZeneca was given a new GBX 8,500 ($111.07) price target on by analysts at Bank of America Corp. They now have a “buy” rating on the stock.
  • 9/11/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Citigroup Inc. They now have a £100 ($130.67) price target on the stock, up previously from GBX 7,000 ($91.47).
  • 9/10/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 5,700 ($74.48) price target on the stock.
  • 9/10/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Societe Generale.
  • 9/9/2019 – AstraZeneca had its price target raised by analysts at Deutsche Bank AG from GBX 7,600 ($99.31) to GBX 7,800 ($101.92). They now have a “buy” rating on the stock.
  • 9/9/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/6/2019 – AstraZeneca had its price target raised by analysts at Barclays PLC from GBX 7,800 ($101.92) to GBX 8,000 ($104.53). They now have an “overweight” rating on the stock.
  • 9/6/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..
  • 9/3/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 9/2/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 9/2/2019 – AstraZeneca was upgraded by analysts at Deutsche Bank AG to a “buy” rating. They now have a GBX 7,600 ($99.31) price target on the stock, up previously from GBX 7,200 ($94.08).
  • 8/29/2019 – AstraZeneca had its “neutral” rating reaffirmed by analysts at Jefferies Financial Group Inc.
  • 8/28/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital. They now have a GBX 6,400 ($83.63) price target on the stock.
  • 8/28/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/27/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 8/26/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 8/21/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG.
  • 8/21/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/20/2019 – AstraZeneca was given a new GBX 5,500 ($71.87) price target on by analysts at Goldman Sachs Group Inc. They now have a “sell” rating on the stock.
  • 8/20/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/20/2019 – AstraZeneca had its “buy” rating reaffirmed by analysts at Shore Capital.
  • 8/16/2019 – AstraZeneca had its price target raised by analysts at Barclays PLC from GBX 7,600 ($99.31) to GBX 7,800 ($101.92). They now have an “overweight” rating on the stock.
  • 8/15/2019 – AstraZeneca was given a new GBX 7,900 ($103.23) price target on by analysts at JPMorgan Chase & Co.. They now have a “buy” rating on the stock.
  • 8/14/2019 – AstraZeneca had its “sell” rating reaffirmed by analysts at UBS Group AG. They now have a GBX 5,700 ($74.48) price target on the stock, up previously from GBX 5,400 ($70.56).
  • 8/14/2019 – AstraZeneca had its “hold” rating reaffirmed by analysts at Liberum Capital.
  • 8/12/2019 – AstraZeneca had its “overweight” rating reaffirmed by analysts at JPMorgan Chase & Co..

LON:AZN traded down GBX 136 ($1.78) during midday trading on Friday, hitting GBX 6,916 ($90.37). 2,428,757 shares of the company were exchanged, compared to its average volume of 2,310,000. The company has a fifty day simple moving average of GBX 7,175.03 and a 200 day simple moving average of GBX 6,504.73. AstraZeneca plc has a fifty-two week low of GBX 5,312 ($69.41) and a fifty-two week high of GBX 8,227.88 ($107.51). The company has a current ratio of 0.95, a quick ratio of 0.74 and a debt-to-equity ratio of 144.48. The company has a market capitalization of $90.73 billion and a PE ratio of 40.40.

AstraZeneca PLC discovers, develops, and commercializes prescription medicines in the areas of oncology, cardiovascular, renal and metabolism, respiratory, autoimmunity, infection, neuroscience, and gastroenterology worldwide. Its marketed products include Arimidex, Casodex/Cosudex, Calquence, Faslodex, Imfinzi, Iressa, Lynparza, Nolvadex, Tagrisso, and Zoladex for oncology diseases; Atacand1/Atacand HCT/Atacand Plus, Brilinta/Brilique, Crestor, Plendil, Seloken/Toprol-XL, Tenormin, and Zestril for cardiovascular diseases; and Bydureon, Byetta, Farxiga/Forxiga, Kombiglyze XR, Komboglyze, Onglyza, Qtern, Symlin, Xigduo, and Xigduo XR for metabolic diseases.

See Also: Technical Indicators – What is a Golden Cross?

Receive News & Ratings for AstraZeneca plc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AstraZeneca plc and related companies with MarketBeat.com's FREE daily email newsletter.